Cyclooxygenase-2 (COX-2) is expressed in 40% of human invasive breast cancers. Bone is the predominant site of metastasis in case of breast cancer. We investigated the role of COX-2 in a suitable mouse model of breast cancer metastasis to bone using the whole-body luciferase imaging of cancer cells. We provide several lines of evidence that COX-2 produced in breast cancer cells is important for bone metastasis in this model including (1) COX-2 transfection enhanced the bone metastasis of MDA-435S cells and (2) breast cancer cells isolated and cultured from the bone metastases produced significantly more prostaglandin E 2 (an important mediator of COX-2) than the parental injected cell populations of breast cancer cells. Next, we found that a COX-2 inhibitor, MF-tricyclic, inhibited bone metastasis caused by a boneseeking clone both in prevention regimen (in which case mice started receiving MF-tricyclic 1 week before the injection of cancer cells) and in treatment regimen (in which case mice received MF-tricyclic after the development of bone metastasis). These studies indicate that COX-2 produced in breast cancer cells may be vital to the development of osteolytic bone metastases in patients with breast cancer, and that COX-2 inhibitors may be useful in halting this process.
Introduction
Cyclooxygenase (COX) enzymes, COX-1 and COX-2, mediate the production of prostaglandins and thromboxanes from arachidonic acid. COX-1 is expressed constitutively, whereas COX-2 is induced in inflammation and cancer. The extracellular stimuli that induce COX-2 include growth factors, cytokines, tumor promoters, hypoxia, ionizing radiation and carcinogens (reviewed by Singh and Lucci, 2002; Howe and Dannenberg, 2003; Wang and DuBois, 2004) . COX-2 is overexpressed in most human epithelial cancers and has been linked to various aspects of cancer progression both early and late in the process. Epidemiological studies have reported a significant reduction in the incidence of human gastrointestinal cancers with COX inhibition by nonsteroidal anti-inflammatory drugs (NSAIDS) (Shaheen et al., 2002) . Although the evidence for breast cancer prevention is less strong, a recent metaanalysis of 14 studies (six cohort, eight case-controlled) gave a combined estimate of a reduced relative risk of 0.82 (95% confidence interval 0.75-0.89) with regular NSAID use (Khuder and Mutgi, 2001) .
There is evidence to implicate COX-2 in breast cancer tumorigenesis. One study showed that 56% of infiltrating mammary carcinomas and intraductal carcinomas expressed significant levels of COX-2, whereas benign breast tissue at least 1 cm from a malignant lesion did not express COX-2 (Soslow et al., 2000) . In a murine model of metastatic breast cancer, prostaglandin E 2 (PGE 2 ) levels are positively correlated with increased tumorigenic and metastatic potential (Kundu et al., 2001) . Perhaps the most convincing evidence that COX-2 causes breast cancer in animals comes from transgenic mice in which COX-2 was overexpressed in mammary tissue by using the mouse mammary tumor virus (MMTV) long-terminal repeat promoter. More than 85% of these mice developed tumors, indicating that COX-2 overexpression alone is sufficient to cause breast tumors (Liu et al., 2001) . Ristimaki et al. (2002) analysed the expression of COX-2 protein by immunohistochemistry in tissue array specimens of 1576 invasive breast cancers. Moderate to strong expression of COX-2 protein was observed in 37.4% of the tumors, and it was associated with unfavorable distant disease-free survival. Elevated COX-2 expression was associated with large tumor size, high histological grade, negative hormone receptor status, high proliferation rate (identified by , high p53 expression and the presence of human epidermal growth factor receptor 2 (HER 2) oncogene amplification, along with axillary node metastases and a ductal type of histology. These results indicate that elevated COX-2 expression is more common in breast cancers with poor prognostic characteristics and is associated with an unfavorable outcome.
We are investigating the mechanisms and biochemical pathways through which COX-2 contributes to various aspects of breast cancer progression, including metastasis. In this study, using a suitable mouse model of breast cancer metastasis, we show that COX-2 overexpression in breast cancer cells correlates with increased metastasis to bone. Starting with the heterogeneous populations of breast cancer cells, cells overexpressing PGE 2 were favored at the sites of bone metastases in the mouse model. Thus, our studies provide further evidence for the role of COX-2 in breast cancer metastasis to bone. We also provide evidence that a COX-2-specific inhibitor, (3-(3,4-difluoropentyl)-4-[4-(methylsulfonyl) .phenyl]-2(5H)-furanone) (MF)-tricyclic, halts breast cancer metastasis to bone in this pre-clinical mouse model.
Results

COX-2 overexpression increases bone metastasis of MDA-435S cells
To determine whether COX-2 overexpression in breast cancer cells would enhance breast cancer metastasis to bone, we utilized a nude mouse model in which cancer cells are inoculated into the left ventricle of female mice. Others have shown previously that MDA-435 cells yield efficient bone metastasis in this model, affecting 100% of the injected mice (Harms and Welch, 2003) . These cells express a low level of COX-2 (Gilhooly and Rose, 1999) . Therefore, to ask whether COX-2 overexpression would enhance bone metastasis (either kinetically or overall burden), we co-transfected MDA-435S cells with a COX-2 expression vector, pSG5-COX2 (encoding human COX-2 protein) and pEF1a-Luc-IRES-Neo vector (encoding luciferase protein and neomycin resistance). After selecting the stably transfected cells in 0.4 mg/ml geneticin, we analysed them for luciferase activity and COX-2 expression. The pEF1a-Luc-IRES-Neo vector allows a long-lasting and relatively high-level stable luciferase expression in the absence of geneticin and after injecting into mice. As shown in a Western blot, COX-2 protein level was significantly increased in COX-2-transfected cells as compared to luciferase-transfected MDA-435S cells (Figure 1a ). The COX-2 band is not visible in control MDA-435S cells at this short exposure of the X-ray film. To obtain a better estimate of the COX-2 protein and its enzyme activity, we measured the production of a one of the prostaglandins, PGE 2 , in transfected cells. PGE 2 is the major mediator of COX-2 in breast cancer cells. Of importance, the COX-2-transfected MDA-435S cells produced significantly higher level of PGE 2 (approximately 22-fold) as compared to the control cells transfected with the luciferase vector ( Figure 1a) . We conclude that the recombinant COX-2 protein is functional in the transfected cells.
To determine whether COX-2 overexpression in MDA-435S cells would increase their metastasis to bone, we injected the left cardiac ventricle of two groups of five female nude mice with 0.1 million cells of either MDA-435S cells stably transfected with luciferase alone or with luciferase plus COX-2 (Figures 1b). Starting at day 28, we quantitated the metastasis on a weekly basis until day 56 by whole-body luciferase imaging. We measured the relative rate of bone metastasis in mice as the relative amount of light produced from the luciferase activity in breast cancer cells as radiance flux per second using Xenogen Living Image software (Figure 1b) . Average radiance flux per mouse in mice injected with control and COX-2 transfected cells (data derived from Figure 1b ) is shown in Figure 1c for comparing the groups. The P-values of F-test of the fixed effects were: treatment 0.635, day o0.0001, day Â treatment 0.284. The P-values for comparing treated vs control on days 28, 35, 42, 49 and 56 were 0.628, 0.265, 0.089, 0.064 and 0.078, respectively. Based on the observed data, on day 56, the mean and standard deviation of log-transformed radiance flux for the MDA-435S group were 2.79 and 0.34; the mean and SD for the MDA-435S COX-2 group were 3.91 and 0.43. With five samples for MDA-435S and three samples for MDA-435S COX-2, we had 74% of power to detect a difference of 1.12 in the mean of log-transformed radiance flux at a significance level of 0.05 using a two sample Satterwaite t-test. Furthermore, power is relevant post-study only for statistically nonsignificant results. For significant P-values, power is not relevant.
At the end of the experiment, we killed mice to confirm pathologically that the metastasis observed by luciferase imaging was indeed localized to bone. We collected the data from imaging the same mice in both ventral and dorsal positions and obtained similar results with the exception that signal intensities were lower in dorsal position than in ventral position, presumably owing to differences in the depth of metastatic loci from the skin. These data showed clearly that COX-2 overexpression significantly increased metastasis in this mouse model of breast cancer metastasis to bone.
Increased PGE 2 production in bone-seeking clones of breast cancer cells We hypothesized that if COX-2 protein expressed in breast cancer cells confers a functional advantage on cells in causing bone metastasis, one might expect that starting from a heterogeneous population of cells in culture, cells with a higher level of COX-2 activity would be selected at the site of bone metastases. To test this, we injected breast cancer cells into left cardiac ventricle of female nude mice, and upon the development of bone metastasis, isolated and cultured cells from the metastasis sites at tibia/femur. In this manner, we isolated such bone-seeking clones (BSCs) from breast cancer cell populations representing a wide range of PGE 2 production, including both untransfected and COX-2-transfected MDA-231 and MDA-435S cells (Figure 2 ). We analysed the BSCs generated from several mice in this manner for the COX-2 activity (by measuring PGE 2 production) and compared these values with those from COX-2 in breast cancer metastasis to bone B Singh et al the parental cells. These data show that the BSCs produce an increased level of PGE 2 as compared to the heterogeneous mixed population of cells that were injected into mice (Figure 2a and b). This was true in all cases irrespective of whether we used untransfected or COX-2-transfected MDA-231 or MDA-435S cells. These results support our hypothesis and suggest that PGE 2 production in breast cancer cells must confer some functional advantage on them so that they complete a cascade of events leading to successful bone metastasis.
Inhibition of bone metastasis with a COX-2 inhibitor Next, we evaluated the role of COX-2 in causing bone metastasis by an alternative experimental approach involving the use of a COX-2-specific inhibitor, MF-tricyclic. These experiments had two objectives: (1) to confirm the observations described above that COX-2 in breast cancer cells is important for bone metastasis by showing that a COX-2 inhibitor would inhibit bone metastasis and (2) to demonstrate in the pre-clinical mouse model that a COX-2 inhibitor would be effective in preventing and treating breast cancer metastasis to bone. We chose to use MF-tricyclic, a highly selective COX-2 inhibitor, in diet at a concentration (67 mg per kg diet; approximately 13 mg/kg of mouse weight/day) that has been shown to be effective in inhibiting colon cancer in a mouse model (Lal et al., 2001) . First, to evaluate the effect of MF-tricyclic in a prevention mode the treatment group of five mice was fed on the MF-tricyclic diet for 7 days before injecting them with the BSC-12 cells. Then the mice were Mice were imaged weekly starting at day 28, and relative luciferase signal (shown as radiance flux in photons per second) over the body of the mice quantitated as described in Materials and methods. Mouse M32 died as a result of cardiac injection. Mouse M31 was killed on day 42 for the isolation of a bone-seeking clone from the tibia/femur. P ¼ 0.05 at day 56 using a two sample Satterwaite t-test. (c) Average metastasis burden per mouse for each group (mice injected with control or COX-2 transfected MDA-435S cells) was determined by averaging the metastases for all the mice at the given time points, for an easy comparison of the groups.
COX-2 in breast cancer metastasis to bone B Singh et al maintained on the MF-tricyclic diet for the duration of the experiment. The control group of five mice was fed on the diet without MF-tricyclic at all times and injected with the BSC-12 cells similar to the treatment group. Relative metastasis burden in individual mice, as measured by whole body luciferase imaging of mice at weekly intervals from day 20 to 34, is shown in Figure 3a ; average metastasis burden per mouse in control and treatment groups is shown in Figure 3b . The P-values of F-test of the fixed effects were: treatment 0.062, day o0.0001, and day Â treatment 0.013. The P-values for comparing treated vs control on day 20, 27 and 34 were 0.629, 0.151 and 0.0205, respectively. These results showed that, as compared to the control group, MF-tricyclic caused a significant inhibition of bone metastasis at day 34 (Figure 3) .
In a clinical setting, it may not be possible to always use COX-2 inhibitors in prevention regimen. Therefore, from the translational standpoint, it is important to learn whether a COX-2 inhibitor would be effective in a treatment regimen in our pre-clinical model. To address this question, we started by feeding a group of 10 mice on the normal control diet. Fourteen days after injecting BSC-12 cells, mice were luciferase-imaged and then divided into two groups, each group having approximately equal metastases in terms of volume and distribution, as measured in radiance flux. One of these groups continued on the control diet whereas the other group was switched to the MF-tricyclic diet for the remainder of the period. The metastasis burden, measured by luciferase-imaging on a weekly basis, is shown in Figure 4a ; average metastasis burden per mouse in control and MF-tricyclic groups is shown in Figure 4b . The P-values of F-test of the fixed effects were: treatment 0.263, day 0.178 and day Â treatment 0.045. The P-values for comparing treated vs control on day 14, 21 and 28 were 0.818, 0.091 and 0.034, respectively. These results showed that MF-tricyclic caused a significant inhibition of bone metastasis as compared to the control group at day 28 (Figure 4) . The inhibitory effect of MF-tricyclic was evident in two ways: (1) reduced rate of growth of metastasis in the initial period of 35 days (21 days of MF-tricyclic treatment) and (2) longer lag period before the exponential growth of metastasis (Figure 4a ). In this experiment as well as those shown in Figures 1 and 3 , we noted heterogeneity in bone metastasis among mice as it affected variably the femurs, tibias, ribs, thoracic vertebrae, pelvis, skull and maxillofacial regions.
Discussion
Our results indicate that COX-2-mediated production of PGE 2 in breast cancer cells enhances metastasis to bone, a major site of breast cancer metastasis in humans. Main features of the pre-clinical mouse model used in this study included: (1) route of introduction of cancer cells through left ventricle thus allowing efficient metastasis to bone, (2) stable long-term expression of luciferase in breast cancer cells without any selection pressure in the mouse background and (3) ability to image and quantitate metastasis in living mice over time with high sensitivity. One can introduce the desired genetic The cells were exposed to fresh medium containing 10 mM sodium arachidonate for 30 min before collecting the medium for the PGE 2 immunoassay. Po0.02 in all comparisons involving parental cells and BSCs.
COX-2 in breast cancer metastasis to bone B Singh et al changes in cancer cells and evaluate their effect on bone metastasis. We chose to investigate the effect of COX-2 in breast cancer metastasis to bone because (1) COX-2 is expressed in poor-prognosis human breast cancers including those overexpressing HER2 and (2) studies with cell lines and mouse models indicate that COX-2 overexpression in breast cancer cells inhibits apoptosis of breast cancer cells and promotes metastasis (Liu et al., 2001; Basu et al., 2004; Singh et al., 2005) . Other in vitro studies have shown that breast cancer cells can stimulate osteoblasts and stromal cells to produce PGE 2 , which in turn induces osteoclastogenesis thus causing osteolytic bone metastasis (Ono et al., 2002; Morgan et al., 2004) . Our cumulative evidence for the role of COX-2 in bone metastasis is based upon: (1) increased bone metastasis upon COX-2 transfection of breast cancer cells (Figure 1 ), (2) inhibition of bone metastasis (in both prevention and treatment regimens) by MFtricyclic (Figures 3 and 4) and (3) demonstration that BSCs of breast cancer cells produce higher levels of PGE 2 than the parental cell population (Figure 2 ), perhaps reflecting that PGE 2 confers an advantage on breast cancer cells for bone metastasis. Although we have not investigated the mechanism of COX-2-mediated bone metastasis here, there is evidence that PGE 2 induces bone resorption both by stimulating RANKL (receptor activator of NF-kB ligand) production in osteoblasts (Li et al., 2002) and by directly acting on osteoclasts (Fujita et al., 2003) . We also have evidence that COX-2 mediated bone metastasis involves induction of interleukin-8 and interleukin-11 cytokines in breast cancer cells (Singh et al., 2006a, b) , both of which have well-established roles in bone metastasis (Girasole et al., 1994; Bendre et al., 2003; Kang et al., 2003) .
Our criteria to demonstrate that COX-2 produced in breast cancer cells is important for bone metastasis are similar to those employed by others in case of other genes involved in bone metastasis (e.g., see Kang et al., 2003) . The results showing a clonal selection of PGE 2 overproducing breast cancer cells at the site of bone metastasis provide a strong evidence for the role of PGE 2 in this process. In another study, BALB/c-MC cells producing a low level of COX-2 formed osteolytic bone metastasis upon injection into the heart of Balb/c mice (Ono et al., 2002) . Although these authors did not analyse metastatic clones, they found that bone marrow stromal cells adjacent to tumor cells expressed COX-2 protein. Results of our study and those of Ono et al. (2002) indicate that production of PGE 2 in the tumor and/or its microenvironment is important for bone metastasis. Although PGE 2 produced by breast cancer cells has a specific role in bone metastasis, our study does not rule out additional roles of COX-2 in cancer progression, which are not specific to bone metastasis. Role of COX-2 in breast cancer has been demonstrated using several different rodent models, including 7,12-dimethyl-benz(a)anthracene-induced mammary carcinogenesis in rat (Harris et al., 2000) , MMTV-COX-2 and MMTV-HER2 transgenic mouse models (Liu et al., 2001; Howe et al., 2002; Chang et al., 2004) , MMTV-HER2 transgenic/COX-2 knock-out mouse model (Howe et al., 2005) and xenograft mouse models involving inoculation of cancer cells into fat pad (Connolly et al., 2002; Roche-Nagle et al., 2004) . These studies indicate an important role of COX-2 in primary tumor growth, angiogenesis and metastasis. With the use of other pre-clinical models, others have shown that a COX-2 inhibitor celecoxib inhibits angiogenesis and induces apoptosis in breast cancer cells in a mouse model of spontaneous metastasis (Basu et al., 2004) . In another model involving MDA-435-FL-GFP human breast cancer xenografts in nude mice, Zhang et al. (2004) showed that celecoxib inhibits overall tumor burden and lung metastasis. COX-2 could have yet additional roles including a role in the pre-malignant phenotype (Crawford et al., 2004) and a role in suppressing tumor-specific host immune responses (Kundu et al., 2005; Basu et al., 2006) . Our ongoing unpublished studies on the analysis of RNA and protein profiles in COX-2-transfected breast epithelial cells are consistent with the multiple roles of COX-2 in cancer progression and metastasis.
The outcome of tumor metastasis may be influenced at multiple steps in the mouse model. We chose an appropriate model, widely used by others investigating the mechanisms of bone metastasis, to investigate We started by feeding a group of 10 mice on the normal control diet. BSC-12 cells were successfully injected into the left ventricle of 6 out of 10 mice. Fourteen days after injecting BSC-12 cells, mice were luciferase-imaged and then divided into two groups, each group having approximately equal metastases in terms of volume and distribution. One of these groups continued on the control diet whereas the other group was switched to the MF-tricyclic diet for the remainder of the period. Mice were imaged weekly starting at day 20, and relative luciferase signal over the body of the mice was quantitated. Mouse M9801 was killed on day 42 for the isolation of a BSC from a large bone metastasis in a leg. All other mice died of metastasis: M9803 on day 35, M9804 on day 49, M9802 on day 42, and both M9805 and M9606 on day 62 (P ¼ 0.03 at day 28). (b) Average metastasis burden per mouse for each group (control or MF-tricyclic-treated mice) was determined by averaging the metastases for all the mice at the given time points.
COX-2 in breast cancer metastasis to bone B Singh et al whether COX-2 is important for bone metastasis. Although the model has several features making it suitable for our studies, measurement of metastasis by whole-body luciferase imaging does not allow us to distinguish between various steps at which COX-2 could contribute to metastasis. The major contribution of COX-2 could be to support growth at the secondary site but its other roles cannot be ruled out (e.g., inhibition of apoptosis in the bone microenvironment) that could be important in establishing metastasis. Particularly, the initial steps of the process, before the appearance of measurable signal, are least understood.
Several mechanisms could account for the increased COX-2 activity at the metastasis sites: alterations in cancer cells themselves, for example, overexpression of HER-2, or those in the tumor microenvironment, for example, release of transforming growth factorbeta from the bone, could induce COX-2 in cancer cells Hiraga et al., 2006) . To determine whether COX-2 expression in primary breast cancer would be predictive of bone metastasis, we are currently analysing bone marrow micrometastasis in breast cancer patients (A Lucci, S Krishnamurthy, B Singh, manuscript in preparation). The results of this clinical study support our hypothesis regarding the role of COX-2 in bone metastasis. Our results of this study in the mouse model, particularly those obtained with the COX-2 inhibitor, provide support for the clinical trials with the COX-2 inhibitors to halt breast cancer metastasis to bone.
Materials and methods
Cells and DNA transfection
The human breast cancer cell lines (MDA-231 and MDA-435S) were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained in Rosewell's Park Memorial Institute (RPMI) 1640 medium, supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin, in a humidified 5% CO 2 atmosphere. COX-2 overproducing cells were generated by co-transfecting breast cancer cell lines with a human COX-2 expression vector pSG5-COX2 (Guo et al., 1996) 
Detection of COX-2 by Western immunoblotting
Cell lysates were prepared by scraping the cells in a sample buffer for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) containing 62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% 2-mercaptoethanol, 10% glycerol and 0.025% bromophenol blue, and boiling immediately for 5 min followed by centrifugation for 15 min at 14 000 r.p.m.
in a microcentrifuge at room temperature. Proteins were resolved by SDS-PAGE on an 8% gel and then electroblotted onto nitrocellulose membrane. A lane containing pre-stained molecular weight markers (Diversified Biotech, Boston, MA, USA) was always included during SDS-PAGE. The nitrocellulose membrane was pre-incubated with the blocking agent to reduce nonspecific protein binding and then incubated with an anti-COX-2 monoclonal antibody (Cayman Chemical, Ann Arbor, MI, USA). After incubation with the sheep anti-mouse IgG conjugated to horseradish peroxidase, the blots were processed with the ECL Advance Western blot detection reagents (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer's instructions. The filters were stripped and re-probed with a monoclonal b-actin antibody (Sigma Chemical Company, St Louis, MO, USA), to serve as gel loading controls.
PGE 2 assay
The level of PGE 2 released by breast cancer cells was measured by a colorimetric enzyme immunoassay using a kit (Cayman Chemical Company, Ann Arbor, MI, USA) as described previously by others . The growth medium of the cells was replaced with fresh medium containing 10 mM sodium arachidonate 30 min before collecting the sample for the assay. The samples were stored frozen at À801C before the assay. The assay utilizes 96-well plates coated with goat anti-mouse immunoglobulin (IgG) that is incubated with limited amounts of anti-PGE 2 monoclonal antibody and a mixture of fixed amount of acetylcholine esterase-coupled PGE 2 and the growth medium containing PGE 2 . After washing the wells, the bound acetylcholine esterase is assayed by a colorimetric reaction. The assay is based on competition between free PGE 2 and acetylcholine esterase-coupled PGE 2 for binding to a fixed number of antibody molecules. Thus, the amount of color produced is inversely proportional to the amount of PGE 2 present in the medium. These assays were carried out on two parallel cell cultures assayed in duplicate. We normalized the PGE 2 production on an equal protein basis by measuring protein concentration in cell lysates from two parallel cell cultures assayed in triplicate using a protein assay kit (Bio-Rad, Hercules, CA, USA).
Whole-body luciferase imaging of mice Breast cancer cell lines (MDA-435S and MDA-231) were stably transfected with luciferase alone or luciferase plus COX-2. After confirming that these cells produce luciferase and COX-2 (by Western blot and PGE 2 assay), we injected 100 000 cells (in 0.1 ml RPMI 1640 medium without serum and phenol red) into left cardiac ventricle of 4-week-old female athymic nude mice (Harlan, Indianapolis, IN, USA) with a 27-gauge syringe as described by others (Arguello et al., 1988) . Injections were carried out under deep anesthesia with pentobarbital. Tumors in mice were visualized by whole-body luciferase imaging with IVIS imaging system 100 (Xenogen Corporation, Alameda, CA, USA). Briefly, 1 mg potassium salt of D-luciferin in 0.1 ml phosphate-buffered saline was injected intraperitonially with a 25-gauge syringe. Then mice were kept under anesthesia with isofluorane. Starting at 10 min after the luciferin injection, images were collected for 5 min each in ventral and dorsal position, respectively. Relative tumor metastasis burden in mice was calculated with the Living Image software version 2.50 (Xenogen).
X-rays
To confirm bone metastasis by X-rays, mice were deeply anesthetized with an intraperitonial injection with COX-2 in breast cancer metastasis to bone B Singh et al pentobarbital and X-rayed in prone and lateral positions at 35 kV for 6 s with an imaging system (Faxitron X-ray Corporation, Wheeling, IL, USA).
Isolation of bone-seeking clones
For the isolation of bone-seeking cells, mice were killed after detecting metastases in hind limbs by luciferase imaging. Tumor cells were flushed out of bone with a syringe, washed with phosphate buffered saline, and cultured in normal complete RPMI 1640 medium as described by others (Kang et al., 2003) .
Statistical analysis
Statistical analysis was performed using two-sample t-test (Figure 2) , and a linear mixed model with repeated measures (Figures 1, 3 and 4) . The linear mixed model was fitted to analyse radiance flux using SAS (version 9.0). Radiance flux was first transformed using the natural log scale to better fit the assumptions of linear mixed model. The linear models include fixed effects of treatment, day effect as continuous variable, and the interaction between day and treatment (treated vs. control), with repeated measures over time. We used the firstorder autoregressive covariance structure for the MDA-435S COX-2 and the treatment with MF-tricyclic data sets, and used the Compound Symmetry covariance structure for the prevention with MF-tricyclic data set. Owing to missing observations at the later time points, the time points included in the linear mixed model for MDA-435S COX-2, prevention with MF-tricyclic, and treatment with MF-tricyclic were 5, 3, and 3, respectively. Comparisons between the treated and control group at each time were made within the linear mixed models. To analyse our data, we tried difference covariance structures including (1) autoregressive (AR (1)), (2) heterogeneous autoregressive (ARH (1)), (3) compound symmetry (CS), and (4) heterogeneous compound symmetry (CSH). ARH (1) and CSH take into account the heterogeneity between animals. In the final models, we chose the covariance structure based on the Akaike's information criterion, Bayesian information criterion, and simplicity. P-values of 0.05 or less were considered significant.
